Impacts of anticancer drug parity laws on mortality rates
Impacts of anticancer drug parity laws on mortality rates
复制标题
抗癌药物平价法对死亡率的影响
DOI：
10.1016/j.socscimed.2021.113714
复制
发表时间：
2021
影响因子：
5.4
通讯作者：
Noguchi Haruko
中科院分区：
文献类型：
--
作者：
Shen Yichen;Noguchi Haruko
本研究采用双重差分法调查抗癌药物平价法对美国死亡率的影响。利用2004年至2017年压缩死亡率文件的数据，我们表明抗癌药物平价法降低了头颈部恶性肿瘤的死亡率，但对其他类型的恶性肿瘤没有影响。我们还排除了可能影响抗癌药物平价法与恶性肿瘤死亡率之间关系的保险扩张渠道。我们的结果对于各种规格和伪造测试都是稳健的。我们的研究结果表明，提供平等获得口服抗癌药物的机会是预防过早死亡的有效工具。
This study investigates the impacts of anticancer drug parity laws on mortality rates in the United States using a difference-in-differences approach. Using data from 2004 to 2017 Compressed Mortality Files, we show that the anticancer drug parity laws reduce the mortality rate for head/neck malignant cancers but have no impact on malignant cancers of other types. We also rule out an insurance expansion channel that may influence the relationship between anticancer drug parity laws and malignant cancer mortality. Our results are robust to various specifications and falsification tests. Our findings imply that providing equal access to oral anticancer drugs is an effective tool for the prevention of premature mortality.